Terfenadine
Terfenadine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target potassium voltage-gated channel subfamily H member 2, cytochrome P450 2J2, and potassium voltage-gated channel subfamily H member 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Otitis media with effusion | D010034 | EFO_0007415 | H65.3 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic urticaria | D000080223 | L50.8 | — | 1 | 2 | — | — | 3 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 3 | — | — | 3 |
| Pterygium | D011625 | H11.0 | — | — | 1 | — | — | 1 | |
| Inflammation | D007249 | — | — | 1 | — | — | 1 | ||
| Chronic progressive multiple sclerosis | D020528 | — | — | 1 | — | — | 1 | ||
| Pemphigus | D010392 | EFO_1000749 | L10 | — | — | 1 | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | 1 | — | — | 1 | |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | 1 | 4 | — | — | — | 5 | ||
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Medulloblastoma | D008527 | — | 1 | — | — | — | 1 | ||
| Ependymoma | D004806 | — | 1 | — | — | — | 1 | ||
| Graft rejection | D006084 | — | 1 | — | — | — | 1 | ||
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Circulating neoplastic cells | D009360 | — | 1 | — | — | — | 1 | ||
| Hepatitis d | D003699 | EFO_0007304 | — | 1 | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 1 | — | — | — | 1 | |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 3 | 3 | |
| Allergic rhinitis | D065631 | J30.9 | — | — | — | — | 2 | 2 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Actinic keratosis | D055623 | L57.0 | — | — | — | — | 1 | 1 | |
| Endolymphatic hydrops | D018159 | EFO_1000918 | H81.0 | — | — | — | — | 1 | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | 1 | 1 | |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TERFENADINE |
| INN | terfenadine |
| Description | Terfenadine is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 50679-08-8 |
| RxCUI | 42330 |
| ChEMBL ID | CHEMBL17157 |
| ChEBI ID | 9453 |
| PubChem CID | 5405 |
| DrugBank | DB00342 |
| UNII ID | 7BA5G9Y06Q (ChemIDplus, GSRS) |
Target
Alternate
KCNH2
KCNH2
CYP2J2
CYP2J2
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35219)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,928 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
52 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more